Pregabalin controlled-release - Yuhan

Drug Profile

Pregabalin controlled-release - Yuhan

Alternative Names: Pregabalin CR - Yuhan; Pregabalin SR; YHD 1119; YHD1119 A; YHD1119 B; YHD1119 C

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Yuhan
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neurological disorders
  • Phase Unknown Neuropathic pain

Most Recent Events

  • 06 Dec 2016 Yuhan Corporation plans a phase III trial for Neuropathic pain in South Korea (PO) (NCT02985216)
  • 01 Dec 2016 Investigation in Neuropathic pain in South Korea (PO) before December 2016
  • 18 Nov 2016 Phase I development is ongoing in Neurological-disorders (In volunteers) in South Korea (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top